PubMed中文版

检索结果 7119
原始关键字 阿尔茨海默病 治疗 
转化关键字 ((TITLE_ABS:("Alzheimer disease" treatment)) OR (KW:("Alzheimer disease" treatment))) AND SRC:MED 


影响因子

出版日期
文献类型
物种
PubMed ID 42411945
发表日期 2026-07-06
作者 Nakamura Y, Tsushio T, Tanahashi M, Suganami H, Omori T, Nishiyama K, Aoki H, Nagakura N.
文献标题 Post Hoc Subgroup Analysis by Disease Severity in a Non-Inferiority Trial of Donepezil 27.5 mg Transdermal Formulation in Japanese Patients With Mild-to-Moderate Alzheimer Disease.
原始出处 Alzheimer Dis Assoc Disord
影响因子 1.4   期刊引文指标 0.6

PubMed ID 41824288
发表日期 2026-07-01
作者 Saad HM, Atef E, Aboushouk AA, Waheeb TS, Elsayed AE, Mohammed SAA.
文献标题 Cross-talk between pyroptosis and miRNAs in Alzheimer disease neuropathology, therapeutic targeting of NLRP inflammasomes, and recent advances in nanoparticle-targeted therapy.
原始出处 J Neuropathol Exp Neurol
影响因子 3   期刊引文指标 0.96

PubMed ID 42202980
发表日期 2026-05-26
作者 Sánchez-Valle R, Alcolea D, Amer Ferrer G, Balasa M, Casado Naranjo I, Fortea J, Lladó A, Lleó A, Montes AM, Martinez Lozano L, Martínez-Lage P, Matias-Guiu JA, Mendioroz M, Perez Martinez DA, Ripoll GP, Riverol M, Sanchez-Juan P, Bondía HV, Spanish Society of Neurology’s Behavioural Neurology, Dementia Study Group working group for the appropriate use of anti-amyloid monoclonal antibody treatment.
文献标题 Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.
原始出处 Neurologia (Engl Ed)
影响因子

PubMed ID 41240389
发表日期 2026-08-01
作者 Jahanmehr D, Ahmadi A, Fadaei M, Sangi Nasab Lahijan A, Shafiee Sabet M, Kalantari Dehaghi H, Asadi-Golshan R.
文献标题 The Ketogenic Diet: A Possible Intervention for Improving Hippocampal Function in Neurological Disorders.
原始出处 Nutr Rev
影响因子 4.9   期刊引文指标 0.73

PubMed ID 42128444
发表日期 2026-05-13
作者 Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, Ye W, Ryan S, Doty EG.
文献标题 Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.
原始出处 Neurol Clin Pract
影响因子 3.2   期刊引文指标 0.81

PubMed ID 41926104
发表日期 2026-05-01
作者 Devanand DP, Wei R, Qian M.
文献标题 Treatment of Early Symptomatic Alzheimer Disease With Valacyclovir-Reply.
原始出处 JAMA
影响因子 55   期刊引文指标 11.47

PubMed ID 41926105
发表日期 2026-05-01
作者 Kosaka M, Kami M.
文献标题 Treatment of Early Symptomatic Alzheimer Disease With Valacyclovir.
原始出处 JAMA
影响因子 55   期刊引文指标 11.47

PubMed ID 41881052
发表日期 2026-03-25
作者 Noguchi-Shinohara M, Ono K.
文献标题 Successful Amyloid Removal by Donanemab Treatment in a Female Patient With Alzheimer Disease: A Case Report.
原始出处 Neurology
影响因子 8.5   期刊引文指标 2.54

PubMed ID 42015793
发表日期 2026-04-01
作者 Gao L, Watson R, Yassi N.
文献标题 Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia.
原始出处 Med J Aust
影响因子 8.5   期刊引文指标 1.56

PubMed ID 41405876
发表日期 2026-02-10
作者
文献标题 Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: Research Summary.
原始出处 JAMA
影响因子 55   期刊引文指标 11.47

PubMed ID 41667287
发表日期 2026-03-04
作者 Casper A, Bolin J.
文献标题 Alzheimer Disease and the Utility of PET.
原始出处 J Nucl Med Technol
影响因子 1.3   期刊引文指标 0.42

PubMed ID 41405855
发表日期 2026-02-01
作者 Devanand DP, Wisniewski T, Razlighi Q, Qian M, Wei R, Andrews HF, Acosta EP, Bell KL, Pelton GH, Deliyannides D, Perrin AC, Caccappolo E, Gershon AA, Prasad KM, Kreisl WC, Mintz A, Huey ED.
文献标题 Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.
原始出处 JAMA
影响因子 55   期刊引文指标 11.47

PubMed ID 41575410
发表日期 2026-01-23
作者 Neth BJ, Graff-Radford J, Cogswell PM, Johnson DR, Botha H, McCarter SJ, Jones DT, Conkins MM, Hardin DB, Spence JJ, Rhegness CL, Allen LA, Coburn RP, Pounders JD, Burkett BJ, Pillai JJ, Day GS, Graff-Radford NR, Lachner C, Messina SA, Jain MK, Stricker NH, Machulda MM, Fields JA, Boots EA, Aduen PA, Barnard LR, Remold MA, Anderlik AM, Asleson KM, Martin LL, Klaassen JA, Larsen JJ, Algeciras-Schimnich A, Bornhorst JA, Rumilla AM, Jack CR, Boeve BF, Knopman DS, Petersen RC, Ramanan VK.
文献标题 Establishing an Alzheimer Disease Therapeutics Clinic: Experience From a Year of Evaluations.
原始出处 Mayo Clin Proc
影响因子 6.7   期刊引文指标 1.6

PubMed ID 41176545
发表日期 2025-11-02
作者 El Hajj W, Pujo-Menjouet L, Tine LM, Volpert V.
文献标题 Modelling of anti-inflammatory treatment in the Alzheimer disease: optimal regimen and outcome.
原始出处 Bull Math Biol
影响因子 2.2   期刊引文指标 0.65

PubMed ID 41082199
发表日期 2025-12-01
作者 Lu M, Kim MJ, Collins EC, Shcherbinin S, Ellinwood AK, Yokoi Y, Brooks DA, Hansson O, Knopman DS, Sims JR, Mintun MA.
文献标题 Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
原始出处 JAMA Neurol
影响因子 21.3   期刊引文指标 6.16

PubMed ID 41359335
发表日期 2025-12-01
作者 Cantoni V, Casula EP, Tarantino B, Cupidi C, Huber N, Altomare D, Premi E, Zummo E, Esposito R, Leonardi C, Herukka SK, Solje E, Ferrari A, Cotelli MS, Gasparotti R, Martorana A, Fracassi C, Santarnecchi E, Koch G, Haapasalo A, Grassi M, Benussi A, Borroni B.
文献标题 Home-Based Gamma Transcranial Alternating Current Stimulation in Patients With Alzheimer Disease: A Randomized Clinical Trial.
原始出处 JAMA Netw Open
影响因子 9.7   期刊引文指标 2.95

PubMed ID 40955711
发表日期 2025-09-16
作者 Tan A, Wang Z, Aumont E, Li A, Qin X, Yang X, Feng W, Yang J, Li X, Xiao J, Zhou B, Xing Y, Yi Y, Li J.
文献标题 Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China: A Network Analysis.
原始出处 Alzheimer Dis Assoc Disord
影响因子 1.4   期刊引文指标 0.6

PubMed ID 39805666
发表日期 2025-07-01
作者 Ricaurte-Fajardo A, Ivanidze J, Zhang D, Mahmud M, Yasen W, Ravdin L, Pahlajani S, Leon M, Nordvig AS, Chiang GC.
文献标题 Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?
原始出处 AJNR Am J Neuroradiol
影响因子 3.7   期刊引文指标 1.02

PubMed ID 40222353
发表日期 2025-04-14
作者 Felbecker A, Felbecker A, Rouaud O, Rouaud O, Lathuiliere A, Allali G, Sollberger M, Meyer-Heim T, Monsch AU, Lövblad KO, Becker S, Barro-Belaygues N, Popp J, Bürge M, Lindheimer K, Gietl A, Jung HH, Georgescu D, Meyer R, Frisoni GB.
文献标题 Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland.
原始出处 Neurodegener Dis
影响因子 2.6   期刊引文指标 0.62

PubMed ID 37930677
发表日期 2023-12-01
作者 Ballard C.
文献标题 Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimer Disease.
原始出处 JAMA Neurol
影响因子 21.3   期刊引文指标 6.16